申请人:SHANAGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY
公开号:US20160096811A1
公开(公告)日:2016-04-07
Disclosed are benzoisothiazole compounds and a use in the preparation of anti-schizophrenia drugs. The benzoisothiazole compounds of the present invention not only have strong affinity for dopamine D
3
receptor, 5-HT
1A
receptor and 5-HT
2A
receptor, but also can observably improve the symptoms of schizophrenia relevant to apomorphine model and MK-801 model mice, with oral absorption being good, safety being high and side-effect being less, and having developmental value as new anti-neurotic disease drugs. The present invention is the compounds having a structure of general formula (I), or geometric isomers, free alkalies, salts, hydrates or solvates thereof.
本发明涉及苯并异噻唑化合物及其在制备抗精神分裂症药物中的应用。本发明的苯并异噻唑化合物不仅具有与多巴胺D3受体、5-HT1A受体和5-HT2A受体的强亲和力,而且可以明显改善与阿泼吗啡模型和MK-801模型小鼠相关的精神分裂症症状,口服吸收良好,安全性高,副作用少,并具有作为新型抗神经症药物的开发价值。本发明是具有通式(I)结构的化合物,或其几何异构体、自由碱、盐、水合物或溶剂化物。